title: Chronic bronchitis and chronic obstructive pulmonary disease.
abstract: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD). It has numerous clinical consequences, including an accelerated decline in lung function, greater risk of the development of airflow obstruction in smokers, a predisposition to lower respiratory tract infection, higher exacerbation frequency, and worse overall mortality. CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse. Despite its clinical sequelae, little is known about the pathophysiology of CB and goblet cell hyperplasia in COPD, and treatment options are limited. In addition, it is becoming increasingly apparent that in the classic COPD spectrum, with emphysema on one end and CB on the other, most patients lie somewhere in the middle. It is known now that many patients with severe emphysema can develop CB, and small airway pathology has been linked to worse clinical outcomes, such as increased mortality and lesser improvement in lung function after lung volume reduction surgery. However, in recent years, a greater understanding of the importance of CB as a phenotype to identify patients with a beneficial response to therapy has been described. Herein we review the epidemiology of CB, the evidence behind its clinical consequences, the current understanding of the pathophysiology of goblet cell hyperplasia in COPD, and current therapies for CB.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA. victor.kim@tuhs.temple.edu
authors.forename: Victor
authors.initials: V
authors.lastname: Kim
authors.forename: Gerard J
authors.initials: GJ
authors.lastname: Criner
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D005100:Expectorants / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D020397:Goblet Cells; D006801:Humans; D009093:Mucus; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D012907:Smoking / Q000009:adverse effects / Q000503:physiopathology; D016540:Smoking Cessation; D014970:Xanthines / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D000900:Anti-Bacterial Agents; D000975:Antioxidants; D018680:Cholinergic Antagonists; D005100:Expectorants; D005938:Glucocorticoids; D010726:Phosphodiesterase Inhibitors; D014970:Xanthines; C008514:methylxanthine